stockrowEvommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
Follow EVMN
Alert me
Evommune Inc. (EVMN) Return on invested capital
Evommune Inc.'s return on invested capital over the twelve months to 30 June 2026 was −82.5%, up 7.2 percentage points from fiscal 2025 (−89.6%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −89.6% | (89.61) |
| FY2024 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LRMR Larimar Therapeutics, Inc. compare | 0.00% |
| CAMP CAMP4 Therapeutics Corporation compare | 0.00% |
| ABEO Abeona Therapeutics Inc. compare | 0.00% |
| CABA Cabaletta Bio, Inc. compare | 0.00% |
| FATE Fate Therapeutics, Inc. compare | 0.00% |
| EVMN Evommune Inc. | −82.5% |
| VNDA Vanda Pharmaceuticals Inc. compare | −180.2% |
| IMRX Immuneering Corporation compare | −198.4% |
| LXEO Lexeo Therapeutics, Inc. compare | −253.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)